Viral reactivations and co-infections in COVID-19 patients: a systematic review.
COVID-19
Patient characteristics
Systematic review
Viral co-infection
Viral reactivation
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
26 Apr 2023
26 Apr 2023
Historique:
received:
13
12
2022
accepted:
24
02
2023
medline:
28
4
2023
pubmed:
27
4
2023
entrez:
26
4
2023
Statut:
epublish
Résumé
Viral reactivations and co-infections have been reported among COVID-19 patients. However, studies on the clinical outcomes of different viral reactivations and co-infections are currently in limit. Thus, the primary purpose of this review is to perform an overarching investigation on the cases of latent virus reactivation and co-infection in COVID-19 patients to build collective evidence contributing to improving patient health. The aim of the study was to conduct a literature review to compare the patient characteristics and outcomes of reactivations and co-infections of different viruses. Our population of interest included confirmed COVID-19 patients who were diagnosed with a viral infection either concurrently or following their COVID-19 diagnosis. We extracted the relevant literature through a systematic search using the key terms in the online databases including the EMBASE, MEDLINE, Latin American Caribbean Health Sciences Literature (LILACS), from inception onwards up to June 2022. The authors independently extracted data from eligible studies and assessed the risk of bias using the Consensus-based Clinical Case Reporting (CARE) guidelines and the Newcastle-Ottawa Scale (NOS). Main patient characteristics, frequency of each manifestation, and diagnostic criteria used in studies were summarized in tables. In total, 53 articles were included in this review. We identified 40 reactivation studies, 8 coinfection studies, and 5 studies where concomitant infection in COVID-19 patients was not distinguished as either reactivation or coinfection. Data were extracted for 12 viruses including IAV, IBV, EBV, CMV, VZV, HHV-1, HHV-2, HHV-6, HHV-7, HHV-8, HBV, and Parvovirus B19. EBV, HHV-1, and CMV were most frequently observed within the reactivation cohort, whereas IAV and EBV within the coinfection cohort. In both reactivation and coinfection groups, patients reported cardiovascular disease, diabetes, and immunosuppression as comorbidities, acute kidney injury as complication, and lymphopenia and elevated D-dimer and CRP levels from blood tests. Common pharmaceutical interventions in two groups included steroids and antivirals. Overall, these findings expand our knowledge on the characteristics of COVID-19 patients with viral reactivations and co-infections. Our experience with current review indicates a need for further investigations on virus reactivation and coinfection among COVID-19 patients.
Sections du résumé
BACKGROUND
BACKGROUND
Viral reactivations and co-infections have been reported among COVID-19 patients. However, studies on the clinical outcomes of different viral reactivations and co-infections are currently in limit. Thus, the primary purpose of this review is to perform an overarching investigation on the cases of latent virus reactivation and co-infection in COVID-19 patients to build collective evidence contributing to improving patient health. The aim of the study was to conduct a literature review to compare the patient characteristics and outcomes of reactivations and co-infections of different viruses.
METHODS
METHODS
Our population of interest included confirmed COVID-19 patients who were diagnosed with a viral infection either concurrently or following their COVID-19 diagnosis. We extracted the relevant literature through a systematic search using the key terms in the online databases including the EMBASE, MEDLINE, Latin American Caribbean Health Sciences Literature (LILACS), from inception onwards up to June 2022. The authors independently extracted data from eligible studies and assessed the risk of bias using the Consensus-based Clinical Case Reporting (CARE) guidelines and the Newcastle-Ottawa Scale (NOS). Main patient characteristics, frequency of each manifestation, and diagnostic criteria used in studies were summarized in tables.
RESULTS
RESULTS
In total, 53 articles were included in this review. We identified 40 reactivation studies, 8 coinfection studies, and 5 studies where concomitant infection in COVID-19 patients was not distinguished as either reactivation or coinfection. Data were extracted for 12 viruses including IAV, IBV, EBV, CMV, VZV, HHV-1, HHV-2, HHV-6, HHV-7, HHV-8, HBV, and Parvovirus B19. EBV, HHV-1, and CMV were most frequently observed within the reactivation cohort, whereas IAV and EBV within the coinfection cohort. In both reactivation and coinfection groups, patients reported cardiovascular disease, diabetes, and immunosuppression as comorbidities, acute kidney injury as complication, and lymphopenia and elevated D-dimer and CRP levels from blood tests. Common pharmaceutical interventions in two groups included steroids and antivirals.
CONCLUSION
CONCLUSIONS
Overall, these findings expand our knowledge on the characteristics of COVID-19 patients with viral reactivations and co-infections. Our experience with current review indicates a need for further investigations on virus reactivation and coinfection among COVID-19 patients.
Identifiants
pubmed: 37101275
doi: 10.1186/s12879-023-08117-y
pii: 10.1186/s12879-023-08117-y
pmc: PMC10131452
doi:
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
259Informations de copyright
© 2023. Pan American Health Organization.
Références
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Multidiscip Respir Med. 2022 Mar 01;17(1):815
pubmed: 35340709
Biomed J. 2015 Jan-Feb;38(1):70-6
pubmed: 25179711
Cureus. 2020 Jun 15;12(6):e8645
pubmed: 32550096
J Clin Microbiol. 1988 Apr;26(4):662-7
pubmed: 2835389
Cell Death Differ. 2005 Feb;12(2):177-83
pubmed: 15647756
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Cardiovasc Diabetol. 2020 Oct 1;19(1):164
pubmed: 33004045
Balkan Med J. 2022 Jun 16;39(4):301-302
pubmed: 35707922
J Med Case Rep. 2022 Jan 31;16(1):58
pubmed: 35101103
J Clin Pharm Ther. 2021 Aug;46(4):1062-1070
pubmed: 33638257
Nature. 1991 Oct 31;353(6347):858-61
pubmed: 1944559
Sex Transm Infect. 2003 Aug;79(4):276-9
pubmed: 12902573
IDCases. 2021;24:e01111
pubmed: 33842207
Hepatol Res. 2020 Nov;50(11):1211-1221
pubmed: 32761993
Front Immunol. 2021 Jul 05;12:676828
pubmed: 34290701
Eur J Med Res. 2021 Dec 20;26(1):152
pubmed: 34930492
J Immunother Cancer. 2019 Nov 21;7(1):322
pubmed: 31753012
J Med Virol. 2020 Nov;92(11):2870-2873
pubmed: 32530499
J Intensive Care Med. 2022 Sep;37(9):1152-1158
pubmed: 34791940
J Pers Med. 2021 Feb 16;11(2):
pubmed: 33669364
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211040626
pubmed: 34428954
Clin Infect Dis. 2020 Nov 19;71(16):2052-2060
pubmed: 32307550
Infect Dis Now. 2021 May;51(3):296-299
pubmed: 33495765
IDCases. 2022;27:e01402
pubmed: 35036326
Int J Infect Dis. 2021 Mar;104:315-319
pubmed: 33359064
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Shock. 2021 Aug 1;56(2):188-199
pubmed: 33443366
Immun Ageing. 2020 May 27;17:14
pubmed: 32501397
BMJ Open Gastroenterol. 2021 Jan;8(1):
pubmed: 33436481
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
Microorganisms. 2021 Sep 07;9(9):
pubmed: 34576791
Emerg Microbes Infect. 2020 Dec;9(1):761-770
pubmed: 32228226
JAAD Case Rep. 2021 Jun;12:15-17
pubmed: 33816732
Int J Infect Dis. 2020 Jul;96:683-687
pubmed: 32470606
Eur J Neurol. 2020 Sep;27(9):1748-1750
pubmed: 32449248
Indian J Ophthalmol. 2022 Apr;70(4):1410-1412
pubmed: 35326068
World J Clin Cases. 2021 Jul 6;9(19):5266-5269
pubmed: 34307577
Immun Inflamm Dis. 2022 Apr;10(4):e597
pubmed: 35349757
Lancet Rheumatol. 2020 Aug;2(8):e474-e484
pubmed: 32835257
Eur J Clin Invest. 2020 Oct;50(10):e13362
pubmed: 32726868
Future Virol. 2011 Apr;6(4):451-463
pubmed: 21799704
Chin Med J (Engl). 2020 Oct 20;133(20):2410-2414
pubmed: 32842015
J Clin Microbiol. 1993 Dec;31(12):3157-64
pubmed: 7508453
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Precis Clin Med. 2022 May 23;5(2):pbac014
pubmed: 35694714
Ocul Immunol Inflamm. 2021 May 19;29(4):722-725
pubmed: 34228583
Ir J Med Sci. 2022 Jun;191(3):1093-1097
pubmed: 34247308
Pathogens. 2021 Jun 17;10(6):
pubmed: 34204243
J Immunother Cancer. 2018 Jun 11;6(1):51
pubmed: 29891009
Epidemiol Infect. 2021 Jun 16;149:e145
pubmed: 34130765
J Korean Med Sci. 2022 Feb 28;37(8):e61
pubmed: 35226419
J Virol Methods. 1995 Sep;55(1):27-35
pubmed: 8576306
Clin Case Rep. 2020 Nov 12;9(1):148-152
pubmed: 33489151
Infect Dis Now. 2021 Nov;51(8):676-679
pubmed: 34332165
Beni Suef Univ J Basic Appl Sci. 2021;10(1):78
pubmed: 34751250
J Med Virol. 2021 Sep;93(9):5310-5322
pubmed: 34032294
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
PLoS One. 2021 Jul 1;16(7):e0254129
pubmed: 34197543
Hepatology. 2022 Mar;75(3):765-766
pubmed: 34888903
Semin Immunol. 1997 Feb;9(1):1-5
pubmed: 9106302
J Med Virol. 2020 Nov;92(11):2319-2321
pubmed: 32410338
Clin Infect Dis. 2021 Jul 1;73(1):e252-e255
pubmed: 32840571
Intensive Care Med. 2022 Jun;48(6):706-713
pubmed: 35583676
medRxiv. 2022 Dec 06;:
pubmed: 36523412
Immunol Lett. 2020 Sep;225:31-32
pubmed: 32569607
Infect Dis Ther. 2022 Jun;11(3):1229-1242
pubmed: 35471766
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
Diabetes Res Clin Pract. 2020 Oct;168:108374
pubmed: 32805345
Crit Care Explor. 2021 Jul 13;3(7):e0492
pubmed: 34278319
J Med Virol. 2021 Apr;93(4):1850-1851
pubmed: 32970319
Front Immunol. 2021 Sep 20;12:742631
pubmed: 34616404
J Med Virol. 2023 Jan;95(1):e28337
pubmed: 36418241
J Med Virol. 2022 Mar;94(3):1212-1216
pubmed: 34647632
Crit Care. 2020 Nov 23;24(1):657
pubmed: 33228750
PLoS One. 2014 Jun 11;9(2):e98819
pubmed: 24919177
Medicine (Baltimore). 2021 Jan 8;100(1):e23582
pubmed: 33429732
Cell Host Microbe. 2010 Jul 22;8(1):100-15
pubmed: 20638646
Rheumatol Int. 2022 Sep;42(9):1523-1530
pubmed: 35650445
IDCases. 2021;26:e01346
pubmed: 34840957
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Immun Ageing. 2021 Mar 12;18(1):12
pubmed: 33712035
Clin Exp Med. 2022 Aug;22(3):327-346
pubmed: 34424451
Sci Rep. 2021 May 25;11(1):10902
pubmed: 34035353
Microorganisms. 2022 Feb 04;10(2):
pubmed: 35208817
BMC Infect Dis. 2021 Sep 15;21(1):955
pubmed: 34525962
Br J Dermatol. 2020 Dec;183(6):1145-1147
pubmed: 32790074
Virus Res. 2020 Aug;285:198005
pubmed: 32408156
Clin Immunol. 2020 Aug;217:108509
pubmed: 32535188
Front Med (Lausanne). 2021 Oct 04;8:715519
pubmed: 34671616
Medicine (Baltimore). 2022 May 06;101(18):e29027
pubmed: 35550458
Case Rep Ophthalmol Med. 2021 Jul 16;2021:7336488
pubmed: 34336325
Immunity. 1998 May;8(5):615-23
pubmed: 9620682
J Clin Med. 2021 Jun 25;10(13):
pubmed: 34201947
Crit Care. 2021 Dec 6;25(1):417
pubmed: 34872611
J Oral Microbiol. 2013 Oct 25;5:
pubmed: 24167660
Indian J Crit Care Med. 2022 Mar;26(3):376-380
pubmed: 35519914
Crit Care. 2020 Aug 28;24(1):530
pubmed: 32859241
J Cosmet Dermatol. 2021 Dec;20(12):3747-3750
pubmed: 34731523
J Immunol. 1999 Feb 15;162(4):2154-61
pubmed: 9973490